摘要
目的:观察门冬胰岛素30注射液(商品名:诺和锐30)与精蛋白生物合成人胰岛素注射液(预混30R)(商品名:诺和灵30R)治疗初诊2型糖尿病的疗效。方法:将120例初诊2型糖尿病病人,随机分成诺和锐30组和诺和灵30R组,每组各60例,疗程12周,比较两组治疗后空腹和餐后两小时血糖、糖化血红蛋白控制的变化、低血糖发生情况及经济费用。结果:两组病人血糖均得到控制,诺和锐30组餐后2小时血糖控制更理想,低血糖发生率低,但空腹血糖、糖化血红蛋白、其他不良反应如皮疹和体重指数的增加及经济费用2组未见明显区别。结论:诺和锐30比诺和灵30R控制餐后血糖更快更好,且能降低低血糖的发生率。
Objective：To evaluate the clinic effect about using Insulin BIAsp 30 and Novolin 30R treatment in newly diagnosed type 2 diabetic patients before dinings.Methods：120 patients with newly diagnosed type 2 diabetes mellitus were randomized to receive either BIAsp 30 orNovolin 30R twice daily for 12 weeks.The level of fasting plasma glucose（FPG）,2hour postprandial glucose（PPG）,glycosylated hemoglobin A1c（HbA1c）,hypoglycemia and economic expense were compared after treatment.Results： All cases with satisfied blood glucose control,BIAsp 30 was better,especially for 2hour postprandial glucose（PPG）,and was associated with decreased hypoglycemic.however,the level of fasting plasma glucose（FPG）,glycosylated hemoglobin A1c（HbA1c）,Other adverse reactions,such as rash or the increase in BMI and economic expense had no obvious difference.Conclusion： BIAsp 30,given twice daily was more effective than Novolin 30R,especially to 2hour postprandial glucose（PPG） and was associated with decreased hypoglycemic.
出处
《内蒙古中医药》
2012年第6期4-5,共2页
Inner Mongolia Journal of Traditional Chinese Medicine
